- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
SNMMI: PSMA-18F DCFPyL Changes Treatment for PCa Recurrence in Significant Number of Patients with Low PSAs
In a cohort of 85 patients with biomechanical recurrence of prostate cancer and PSA values less than 2 ng/mL, positive findings on PET imaging with PSMA-18F DCFPyL led to treatment changes in the majority of patients who had negative findings on conventional imaging, according to new research presented at the SNMMI conference.
The use of PSMA-18F DCFPyL may be more advantageous than conventional imaging in detecting biomechanical recurrence of prostate cancer in patients with low prostate-specific antigen (PSA) values, according to new research presented at the 2024 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting.
For the retrospective study, researchers evaluated the use of PET PSMA-18F DCFPyL (Pylarify, Lantheus) in 85 patients (mean age of 69) who had occult prostate cancer recurrence and PSA values less than 2 ng/mL. All patients in the cohort had negative computed tomography (CT), magnetic resonance imaging (MRI), ultrasound and positron emission tomography (PET)-choline exams, according to the study authors.
At a six-month follow-up, the researchers found that PET imaging with PSMA-18F DCFPyL led to treatment changes in 75 percent of patients with positive findings (31/41).
Here one can see PET/CT imaging with PSMA-18F DCFPyL that led to modification with a planned radiotherapy treatment for recurrent prostate cancer. (Images courtesy of SNMMI.)
“In PET-PSMA-positive patients, the therapeutic changes found were classified as indicating or changing the planning of salvage radiotherapy treatment and/or initiating systemic treatment with hormone therapy,” noted lead study author Pedro Jose Plana Lopez, M.D., who is affiliated with Hospital Del Mar in Barcelona, Spain, and colleagues.
The study authors noted a median PSA level of 0.08 ng/dL after treatment changes were instituted in patients with positive PET PSMA results.
(Editor’s note: For related content, see “Can an Emerging PET Radiotracer Be a Viable Alternative to Multiparametric MRI for Detecting Prostate Cancer Recurrence?,” “Utilizing AI for Quantitative Assessment of Prostate Cancer Recurrence” and “Emerging PET Radiotracer May Offer Multiple Advantages in Detecting Prostate Cancer.”)
“PET-PSMA is a powerful diagnostic tool for patients with occult biochemical recurrence with PSA < 2ng/mL,” added Lopez and colleagues.
Reference
1. Lopez PJP, Amorelli FG, Cano JSB, et al. PET/CT PSMA-18F DCFPyL promotes treatment changes in occult biochemical recurrence of prostate carcinoma even with low PSA values. Presented at the 2024 Society of Nuclear Medicine and Molecular Imaging Annual Meeting, June 8-11, Toronto, Canada. Available at: https://www.xcdsystem.com/snmmi/program/10OD8Tq/index.cfm . Accessed June 9, 2024.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.
Study Emphasizes PSMA PET Staging of High-Risk, Hormone Sensitive Prostate Cancer
January 4th 2025In patients with high-risk, hormone sensitive prostate cancer who had no evidence of metastasis on conventional imaging, PSMA PET revealed polymetastatic disease in 24 percent of patients and M1 disease staging in 46 percent of patients.
Can MRI and Micro-Ultrasound Guidance Bolster Focal Laser Ablation Outcomes for Prostate Cancer?
January 3rd 2025For patients with localized prostate cancer and PI-RADS 3 or higher lesions, MRI-guided micro-ultrasound multifiber focal laser ablation had an 18 percent recurrence rate at one year, according to newly published research.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
